Fate Therapeutics, Inc. (FATE) Covered Calls
You can sell covered calls on Fate Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for FATE (prices last updated Mon 4:16 PM ET):
| Fate Therapeutics, Inc. (FATE) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 2.27 | +0.25 | 2.22 | 2.25 | 24.7M | - | 0.2 |
| Covered Calls For Fate Therapeutics, Inc. (FATE) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Dec 20 | 2 | 0.55 | 1.70 | 17.6% | 195% | |
| Jan 17 | 2 | 0.10 | 2.15 | -7.0% | -41.9% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; ToleraCyte for the treatment of autoimmune and inflammatory diseases; and FT300 iPSC-derived myeloid derived suppressor cell product candidate for the treatment of autoimmune diseases. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf engineered T-cell product candidates; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California
| Top 10 Open Interest For Dec 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | SAVA covered calls | |
| 2. | SPY covered calls | 7. | XLF covered calls | 2. | CRVS covered calls | |
| 3. | EEM covered calls | 8. | KWEB covered calls | 3. | ANAB covered calls | |
| 4. | FXI covered calls | 9. | TLT covered calls | 4. | APP covered calls | |
| 5. | IWM covered calls | 10. | KRE covered calls | 5. | RCAT covered calls | |
Want more examples? FAST Covered Calls | FAZ Covered Calls
